BUZZ-Street View: Merck signals renewed confidence in growth after Keytruda patent loss
I'm PortAI, I can summarize articles.
Merck has raised its revenue outlook to $70 billion by the mid-2030s, signaling renewed confidence despite the impending loss of its Keytruda patent, which could impact 50% of its revenue. Analysts from Bernstein, BMO Capital Markets, and Citi provided mixed reviews, with Bernstein highlighting the challenges ahead, while BMO noted a newfound confidence in Merck's strategy. Citi acknowledged progress but cautioned that Merck is not yet fully secure against the patent loss's effects.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments